AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo

Link to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]

AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa

Link to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]

AVITA Medical Names David McIntyre as Chief Financial Officer

Link to Full Article • Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory • Interim CFO Tim Rooney Remains with Company as Chief Administrative Officer Valencia, Calif., USA, and Melbourne, Australia, 18 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]

AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, […]

AVITA Medical Added to S&P/ASX 200 Index

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 8 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open […]

AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update

Link to Full Article • U.S. RECELL® System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter • Over half of all U.S. burn centers and surgeons trained on RECELL System Valencia, Calif., USA, and Melbourne, Australia, 31 October 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]

AVITA Medical Announces Listing on Nasdaq – Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market […]

New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars

Link to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]

AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction

Link to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]

AVITA Medical Added to the S&P/ASX 300 Index

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 6 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 […]